Functional dyspepsia is one of those diagnoses that leaves many patients feeling both relieved and frustrated: relieved, because the endoscopy was normal and cancer has been ruled out; frustrated, because the symptoms are very real and affecting daily life. Functional dyspepsia is not “all in the head” — it is a genuine disorder of gastric and duodenal function, with identifiable physiological abnormalities in how the stomach senses and moves food, how the duodenal lining responds to nutrients, and how pain signals are processed. It affects approximately 10–15% of adults globally and the vast majority of patients improve with the right combination of treatments.
What Is Functional Dyspepsia?
Functional dyspepsia (FD) is defined by the Rome IV diagnostic criteria as a disorder of the stomach and duodenum characterised by one or more of the following symptoms, present for at least the last three months with symptom onset at least six months before diagnosis:
- Bothersome postprandial fullness — food persisting in the stomach long after eating
- Bothersome early satiation — feeling full very quickly, preventing completion of a normal meal
- Bothersome epigastric pain — pain in the upper central abdomen
- Bothersome epigastric burning — burning sensation in the upper abdomen (distinct from heartburn, which is retrosternal)
These symptoms must not be explained by structural disease on upper GI endoscopy. A normal OGD is therefore required before the functional dyspepsia diagnosis can be made.
Two subtypes (Rome IV):
- Postprandial Distress Syndrome (PDS): meal-induced symptoms dominate — postprandial fullness and early satiation; underlying gastric sensorimotor dysfunction (impaired accommodation, delayed emptying); more common subtype
- Epigastric Pain Syndrome (EPS): epigastric pain or burning predominant; not necessarily meal-triggered; greater overlap with peptic ulcer disease and GERD; acid suppression most effective here
~40% of patients have features of both subtypes. FD and IBS co-exist in 20–40% of patients — Rome IV allows both diagnoses simultaneously.
What Causes Functional Dyspepsia?
FD is multifactorial — no single cause explains all cases. The major contributing mechanisms:
1. Gastric sensorimotor dysfunction: In ~40% of FD patients, the gastric fundus fails to relax (accommodate) after eating — the reservoir cannot expand → food immediately pressurises the antrum → early satiation and postprandial fullness. Delayed gastric emptying is present in ~25–30% of FD patients. Accelerated duodenal sensitivity to lipids and acid also drives symptoms in many patients.
2. Duodenal mucosal changes: Low-grade duodenal eosinophilia and mast cell activation alter mucosal permeability and sensitise submucosal pain fibres. Post-infectious FD (PI-FD) — developing after acute gastroenteritis — accounts for up to 15% of FD cases; impaired mucosal repair + visceral sensitisation after infection drive ongoing symptoms.
3. Visceral hypersensitivity and central sensitisation: Gastric barostat studies show FD patients feel pain at gastric distension volumes that cause no discomfort in healthy individuals. The CNS amplifies these visceral signals — the same central sensitisation seen in IBS and fibromyalgia. Anxiety and depression (present in ~40–50% of FD patients) increase central sensitisation and impair top-down pain inhibition.
4. H. pylori association: Present in ~40–50% of FD patients in high-prevalence regions. Eradication improves FD in ~8% more patients than placebo (NNT ~12) — modest but real. H. pylori-positive patients are still included in the FD category under Rome IV, recognising that the infection is a risk factor rather than the primary mechanism in most cases.
Symptoms of Functional Dyspepsia
PDS symptoms: meal-triggered postprandial fullness (lasting >2 hours); early satiation (unable to finish normal meals); nausea; occasional vomiting in severe cases.
EPS symptoms: epigastric pain at rest (not just meal-related); epigastric burning (distinct from heartburn); may be partially relieved by eating (mimics duodenal ulcer) or worsened by eating (mimics gastric ulcer).
Symptoms fluctuate — good and bad periods are characteristic, often correlated with stress, diet, sleep quality, and menstrual cycle in women. The normal endoscopy is part of the diagnosis, not a contradiction of it.
How Functional Dyspepsia Is Diagnosed
Functional dyspepsia is a diagnosis of exclusion — structural causes must be ruled out first.
Upper GI endoscopy (OGD): mandatory. Must show no peptic ulcer, gastritis, esophagitis, Barrett’s, or malignancy. In patients under 55 without alarm features, guidelines allow initial “test-and-treat” for H. pylori without immediate endoscopy, but OGD is required to formally establish FD.
H. pylori testing: UBT or stool antigen test recommended for all dyspepsia patients. For the full range of H. pylori testing, see our article on H. pylori infection and stomach health.
Blood tests: FBC (anaemia), CRP (inflammation), ferritin (iron deficiency), coeliac serology (anti-tTG IgA) — coeliac disease is an important mimic of FD.
Gastric emptying scintigraphy: if gastroparesis is suspected (prominent nausea, vomiting, early satiation, imaging food residue) — changes management toward prokinetics.
- Progressive dysphagia
- Unintentional weight loss
- Iron deficiency anaemia or haematemesis
- Palpable upper abdominal mass
- New-onset symptoms aged ≥55
- Family history of upper GI cancer
- Persistent vomiting
Treatment of Functional Dyspepsia
Treatment is stepwise — sequential empirical trials matched to the dominant subtype:
Step 1 — H. pylori eradication (if positive): all H. pylori-positive FD patients should receive eradication therapy. Eradication produces a small but real improvement in a meaningful minority and is the only disease-modifying treatment for FD. For how H. pylori contributes to gastritis and upper GI inflammation, see our article on gastritis: symptoms and causes.
Step 2 — Acid suppression: PPIs (omeprazole 20mg OD or esomeprazole 20–40mg OD) — most effective in EPS; 4–8 week trial; NNT ~7. H2-receptor antagonists (famotidine) are a reasonable alternative. Likely work by reducing acid-mediated duodenal hypersensitivity as well as conventional acid suppression. According to NICE guideline CG184, full-dose PPI for 4–8 weeks is appropriate empirical therapy for dyspepsia without alarm features before endoscopy is performed.
Step 3 — Prokinetics (especially for PDS):
- Domperidone (10mg three times daily before meals): D2 antagonist; improves gastric motility and accommodation; modest but real benefit in PDS; important: avoid in cardiac patients or those with QTc prolongation risk; maximum 4 weeks per course
- Buspirone (10mg three times daily): 5-HT1A agonist; enhances gastric accommodation via vagal relaxation; well tolerated; positive RCT evidence in PDS
- Acotiamide: approved in Japan; positive trials for PDS; limited availability in Western countries
Step 4 — Low-dose antidepressants: the FUNCTIONAL trial (Am J Gastroenterol, 2017) demonstrated amitriptyline 50mg nocte was superior to placebo for FD at 12 weeks. This is a central pain modulator effect (sub-antidepressant dose), not an antidepressant effect. Start at 10–25mg at night; build up over 4–8 weeks. Mirtazapine is useful when weight loss accompanies FD. SNRIs (venlafaxine, duloxetine) are alternatives. Full response takes 8–12 weeks.
Step 5 — Psychological therapies: gut-directed CBT, gut-directed hypnotherapy, and mindfulness-based interventions have strong evidence bases. NNT for gut-directed hypnotherapy in FD is approximately 3 — among the most effective treatments available. These target gut-brain axis dysfunction: reducing central sensitisation, modifying fear-avoidance responses to symptoms, and improving coping. First-line in FD patients with comorbid anxiety, depression, or previous trauma, and for refractory cases. According to the systematic review by Ford et al. in Gut (2020), psychological therapies rank among the most effective treatments for FD across head-to-head comparisons.
Dietary approaches: small, frequent meals; low-FODMAP diet (reduces fermentable carbohydrates and gas production); reduce high-fat foods; food diary to identify individual triggers. For organic upper GI conditions that must first be excluded from FD, see our overview of peptic ulcer disease explained and GERD vs gastritis: what is the difference.
Functional Dyspepsia vs Other Conditions
vs Peptic ulcer disease: both cause epigastric pain, but PUD shows ulceration on OGD and responds definitively to acid suppression + H. pylori eradication. FD has a normal OGD and responds less completely to acid suppression alone.
vs GERD: EPS overlaps clinically with GERD. Key distinction: FD epigastric burning is upper-abdominal; GERD heartburn is retrosternal, often rising toward the throat. pH monitoring separates them.
vs Gastroparesis: FD and gastroparesis overlap — delayed emptying is present in ~25–30% of FD patients. True gastroparesis (diabetes-associated, post-surgical) requires prokinetics as primary therapy and may need nutritional support.
vs IBS: 20–40% of FD patients also meet Rome IV criteria for IBS. The gut-brain dysfunction is shared; management of co-existent FD/IBS benefits from an integrated approach. IBS is predominantly lower GI (cramping, altered bowel habits); FD is upper GI.
Living with Functional Dyspepsia
FD is chronic and relapsing-remitting. ~20–30% remit spontaneously, particularly younger patients after H. pylori eradication. Quality of life during active phases is significantly impaired — often more than in patients with organic disease like mild peptic ulcer. The absence of a structural diagnosis does not correlate with symptom severity.
Effective self-management includes: food and symptom diary to identify personal triggers; regular, small frequent meals; structured stress management (mindfulness, CBT); regular moderate exercise, which modulates gut motility and central sensitisation; and consistent sleep routines. Understanding the gut-brain axis — that the nervous system, not just the stomach, is part of the problem — is often liberating for patients who have been told “there’s nothing wrong” despite genuine symptoms.
The Gut-Brain Axis in Functional Dyspepsia
The gut-brain axis is the bidirectional communication network connecting the enteric nervous system — the 500 million neurons embedded in the gut wall — with the central nervous system via the vagus nerve, spinal afferents, the hypothalamic-pituitary-adrenal (HPA) axis, and circulating gut hormones. In functional dyspepsia, this network is dysregulated in ways that amplify normal visceral sensations into painful or distressing ones.
In healthy individuals, the brain exerts top-down inhibitory control over incoming visceral signals — filtering out the constant stream of normal gut activity and allowing only genuinely significant signals to reach conscious awareness. In FD patients, this inhibitory filter is less effective. Small amounts of gastric distension, normal acid exposure, or minor intestinal gas produce sensations that are disproportionately intense and unpleasant. This is visceral hypersensitivity — the defining sensory abnormality of functional GI disorders.
The HPA axis plays a particularly important role. In patients with high anxiety or past psychological trauma, baseline cortisol levels are dysregulated — and the gut is richly innervated with cortisol receptors. Elevated cortisol accelerates gastric emptying in acute stress but impairs it in chronic stress, alters mucosal permeability, promotes mast cell activation in the duodenal mucosa, and increases inflammatory cytokine release. This creates a physiological feedback loop: stress worsens gut function → worsening gut function amplifies anxiety → which further disrupts gut-brain signalling.
Serotonin (5-HT) is particularly important in this axis — approximately 95% of the body’s serotonin is produced in enterochromaffin cells of the gut mucosa. Serotonin regulates gastric accommodation, gastric emptying, and the sensitivity of visceral afferents. Polymorphisms in serotonin transporter genes are associated with FD susceptibility. Buspirone (5-HT1A agonist) improves gastric accommodation in FD partly by modulating this serotonergic pathway. Low-dose TCAs like amitriptyline work centrally by inhibiting serotonin and norepinephrine reuptake, reducing central sensitisation to visceral pain inputs.
Understanding the gut-brain axis helps explain why effective FD management often requires addressing both ends of the axis simultaneously — not just treating the gut (acid suppression, prokinetics) but also the brain and nervous system (psychological therapies, low-dose antidepressants). The most durable outcomes in FD are achieved when sensorimotor dysfunction and central sensitisation are both addressed.
Post-Infectious Functional Dyspepsia
Post-infectious functional dyspepsia (PI-FD) is one of the most clearly mechanistically defined subgroups of FD. It develops after an acute episode of gastroenteritis — typically within days to weeks — and persists long after the infective agent has cleared. Estimates suggest that up to 15% of FD cases develop in this post-infectious context, and several well-designed prospective studies have confirmed the association.
The pathophysiology of PI-FD involves several interconnected mechanisms. First, the acute infection — whether bacterial (Salmonella, Campylobacter, E. coli), viral (norovirus), or parasitic (Giardia) — damages the mucosal epithelium and disrupts tight junction proteins that maintain the intestinal barrier. This allows luminal antigens and bacterial products to reach the lamina propria and submucosa, triggering a local immune response. In most people, this response resolves completely as the mucosa repairs. In those who develop PI-FD, low-grade mucosal inflammation persists — evidenced by elevated duodenal eosinophils, mast cells, and T-lymphocyte infiltration even when standard biopsies appear normal to routine histology.
Second, the acute infection sensitises the visceral afferent nerve fibres that run alongside the gut mucosa. These nerves are exposed to inflammatory mediators (histamine, prostaglandins, serotonin) during the acute infection — a process that lowers their firing threshold and makes them more reactive to subsequent normal stimuli. This peripheral sensitisation contributes to the visceral hypersensitivity that defines FD.
Third, the psychological impact of a severe acute GI illness — nausea, vomiting, urgency, hospitalisation — can trigger anxiety responses and hypervigilance to GI sensations. The brain learns to interpret gut signals as threatening, reinforcing central sensitisation and creating a self-sustaining feedback loop even after the gut has structurally healed.
PI-FD patients may benefit particularly from low-dose TCAs or SNRIs (targeting central sensitisation and residual mucosal nerve sensitisation) and from gut-directed psychological therapies that address hypervigilance. H. pylori status should still be checked and treated if positive, as concurrent infection can compound mucosal inflammation.
Monitoring Symptoms and Knowing When to Seek Further Evaluation
Most patients with established functional dyspepsia do not need repeat endoscopy unless their symptom pattern changes significantly. Annual or routine repeat OGDs add no clinical benefit once a normal structural baseline has been confirmed. However, certain changes in symptom pattern require prompt medical reassessment, as they may indicate the development of a new organic condition superimposed on existing FD.
Seek prompt medical review if any of the following develop: new progressive dysphagia (difficulty swallowing solid or liquid foods); unintentional weight loss of more than 5% of body weight over 3–6 months; haematemesis (vomiting blood) or melaena (black, tarry stools); new-onset symptoms in a patient aged 55 or over who has previously been symptom-free; anaemia identified on blood testing; or a family history of upper GI cancer in a first-degree relative. These features may need urgent endoscopy, regardless of prior FD diagnosis. For a broader overview of upper abdominal symptoms requiring evaluation and when investigations are urgently needed, see our detailed guide to when stomach pain needs evaluation.
Between clinic appointments, a structured symptom diary is one of the most clinically useful tools available to FD patients. Recording meals, symptoms, timing, severity, and associated factors (stress level, sleep, menstrual cycle, activity level) over 4–6 weeks provides a detailed picture that supports treatment decisions, identifies specific triggers, and demonstrates treatment response objectively. Many patients find that the exercise of keeping a diary also reduces health anxiety around symptoms — by externalising and tracking symptoms, the diary reduces the hypervigilance that amplifies central sensitisation.
Frequently Asked Questions
Functional dyspepsia is not a dangerous or life-threatening condition — it does not cause structural damage, does not progress to cancer, and does not lead to serious complications. However, it significantly impairs quality of life in many patients — affecting the ability to eat normally, work, and socialise. “Serious” in terms of physical risk is low. In terms of quality-of-life impact, it is real and should not be minimised. Treatment can dramatically improve function and wellbeing.
For H. pylori-positive patients, eradication achieves lasting remission in a meaningful subset. For others, FD is typically chronic and relapsing-remitting — not cured, but highly manageable. Approximately 20–30% experience spontaneous long-term remission. Combination approaches (acid suppression, prokinetics, psychological therapy, dietary adjustment) achieve substantial improvement in most patients. For the majority, FD is managed rather than cured, but with effective management most patients live normally with minimal symptom interference.
The most commonly reported triggers are: fatty or fried foods; processed snacks; spicy foods; alcohol; coffee; carbonated drinks; citrus; large portions; fast eating. Individual triggers vary — a systematic food diary is the most reliable way to identify personal patterns. The low-FODMAP diet helps many PDS patients by reducing gastric distension from fermentable carbohydrate. The universally most helpful dietary change is eating smaller, more frequent meals rather than large infrequent ones.
No, but they are closely related. IBS is a functional disorder of the large intestine — characterised by abdominal cramping, bloating, and altered bowel habits. FD is a functional disorder of the stomach and duodenum — characterised by upper abdominal fullness, pain, and early satiation. Both involve gut-brain axis dysfunction and visceral hypersensitivity. They co-exist in 20–40% of patients and respond similarly to psychological treatment approaches. A patient can have both diagnoses simultaneously under Rome IV criteria.
A normal endoscopy means the stomach and duodenum look structurally normal — no ulcers, erosions, or tumours. But endoscopy cannot see physiological abnormalities: impaired gastric accommodation, heightened visceral pain processing, or low-grade mucosal changes at the cellular level. Functional dyspepsia is a disorder of how the stomach and gut-brain axis function, not of what the stomach looks like. The normal endoscopy is part of making the diagnosis — confirming no structural disease — not evidence that there is nothing wrong.
Stress does not directly cause FD, but it powerfully amplifies it. The gut-brain axis — the bidirectional communication network between the GI tract and the CNS — means that psychological stress activates neural pathways that amplify visceral pain. Patients with anxiety, depression, or high life stress report significantly worse FD symptoms. Improvements in psychological state are associated with improvements in GI symptoms. Addressing stress is not instead of treating the gut — it is treating one of the most important drivers of symptom severity.
The best treatment depends on the dominant subtype. For EPS (epigastric pain/burning): PPI is first-line; low-dose TCAs (amitriptyline) are second-line. For PDS (postprandial fullness/early satiation): prokinetics (domperidone, buspirone) and dietary modification are first-line. For both subtypes with psychological comorbidity or refractory symptoms: gut-directed CBT or hypnotherapy offers some of the strongest efficacy evidence. H. pylori eradication should always be done if H. pylori is present. Combination of acid suppression + prokinetic + psychological therapy is often most effective in moderate-to-severe FD.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Alarm features including dysphagia, weight loss, haematemesis, or new symptoms aged ≥55 require urgent medical evaluation before a functional diagnosis is applied.
References
- Tack J et al. Functional dyspepsia. Lancet. 2018;391(10134):1892–1898. Available at: PubMed.
- Ford AC et al. Efficacy of therapies for functional dyspepsia: systematic review and network meta-analysis. Gut. 2020;69(10):1751–1763. Available at: PubMed.
- Moayyedi PM et al. PPI therapy in non-ulcer dyspepsia: systematic review. Am J Gastroenterol. 2017;112(7):988–994. Available at: PubMed.
- NICE guideline CG184: Dyspepsia and gastro-oesophageal reflux disease. 2014 (updated 2019). Available at: nice.org.uk.
- NHS. Dyspepsia (indigestion). Available at: nhs.uk.
This explains so much. I’ve had a normal endoscopy twice and kept being told there’s nothing wrong, but the symptoms are completely real. The distinction between PDS and EPS is something no doctor has ever explained to me — that’s really helpful for understanding which treatments might work best.
Thank you, Sandra — your experience is really common and unfortunately reflects how functional dyspepsia is still poorly communicated to patients. The PDS/EPS distinction directly shapes treatment: EPS tends to respond better to acid suppression (PPIs), while PDS responds better to prokinetics like buspirone or domperidone. Knowing which pattern dominates your symptoms is the most useful starting point for working with your doctor on a targeted approach. We hope the article helps you have a more productive conversation at your next appointment.
I’ve had functional dyspepsia for 3 years and have been through most of these treatment steps. The amitriptyline section is really accurate — it took about 8 weeks to see results and my GP was ready to stop it at 4 weeks when I hadn’t improved yet. Worth persisting. Good to see it explained properly here.